AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HEMOGENYX PHARMACEUTICALS PLC

AGM Information Jan 6, 2021

4938_dva_2021-01-06_b4cdcda4-eb82-4ed0-86c2-e7a11ca0a305.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 8255K

Hemogenyx Pharmaceuticals PLC

06 January 2021

6 January 2021

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Result of General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the General Meeting held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

General Meeting Voting Results

Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2)
1. To grant the Directors the authority to issue the Convertible Loan Notes 152,836,161 99.93% 110,000 0.07% 152,946,161 35.27% 10,000
2. To authorise the allotment of shares and the right to subscribe for or convert any security into shares 152,836,161 99.93% 110,000 0.07% 152,946,161 35.27% 10,000
Special Resolutions Votes for % of votes cast for Votes against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2)
3. To disapply statutory pre-emption provisions 152,836,161 99.93% 110,000 0.07% 152,946,161 35.27% 10,000

(1)        The Company's issued share capital ("ISC") on 4 January 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 433,636,255 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

Enquiries:

Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder [email protected]
Peter Redmond, Director [email protected]
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMEQLFBFFLEBBF

Talk to a Data Expert

Have a question? We'll get back to you promptly.